Yunding New Shine: Plans to acquire 100% equity of Hisen Biopharmaceutical (Singapore) Co., Ltd. for $250 million

On April 8, Ventyx Biosciences issued an announcement, stating that its wholly owned subsidiary, EverSea Medicines (Singapore) Pte. Ltd., on April 7, 2026, entered into an agreement with the seller, Haishen Biopharmaceuticals (Asia) Co., Ltd., to acquire all the equity interests of its wholly owned subsidiary, Haishen Biopharmaceuticals (Singapore) Co., Ltd.

As of December 31, 2025, the target company’s normalized revenue was $82.23 million (approximately RMB 566 million), and EBITDA was $27.27 million (approximately RMB 188 million). The total consideration under the share purchase agreement is $250 million (approximately RMB 1.72B), to be paid in three installments.

The first installment is $150 million (approximately RMB 1.03B), accounting for 60% of the consideration, and will be paid at closing. The second and third installments are each $50 million (approximately RMB 344 million), and are expected to be due in the first quarters of 2028 and 2029, respectively.

The board believes that the consideration represents an approximate 22% discount to the target company’s appraised value of $320 million (approximately RMB 2.2B), is fair and reasonable as a reference, and aligns with the company’s overall interests. The acquisition will help the company expand its market presence in the Asia-Pacific region and diversify its business.

(Ventyx Biosciences announcement)

(Editor: Yang Yan, Lin Chen)

Key words:

                                                            Medical